Pediatric Lupus trial of belimumab plus background standard therapy

Trial Identifier: 114055
Sponsor: GlaxoSmithKline
Collaborator:
Human Genome Sciences Inc., a GSK Company
Start Date: September 2012
Primary Completion Date: January 2018
Study Completion Date: September 2025
Condition: Lupus

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Argentina Ciudad Autonoma de Buenos Aires, Argentina, C1270AAN
Argentina Rosario, Argentina, 2000
Argentina Santa Fe, Argentina, 5400
Canada, AB Calgary, AB, Canada, T3B 6A8
Canada, ON Toronto, ON, Canada, M5G 1X8
Japan Aichi, Japan, 474-8710
Japan Kagoshima, Japan, 890-8520
Japan Miyagi, Japan, 989-3126
Japan Tokyo, Japan, 113-8519
Mexico San Luis PotosI, Mexico, 78240
Peru Lima, Peru, Lima 5
Peru Lima, Peru, Lima 27
Peru Surco, Peru, Lima 33
Poland Lodz, Poland, 91-738
Poland Warszawa, Poland, 02-637
Russian Federation Moscow, Russian Federation, 119435
Russian Federation St Petersburg, Russian Federation, 194100
Russian Federation Tolyatti, Russian Federation, 445846
Spain Espluges de Llobregat, Spain, 08950
Spain Madrid, Spain, 28034
Spain Valencia, Spain, 46026
United Kingdom Bristol, United Kingdom, BS2 8BJ
United Kingdom Liverpool, United Kingdom, L12 2AP
United Kingdom London, United Kingdom, NW1 2PG
United Kingdom London, United Kingdom, WC1N 3JH
United States, AZ Phoenix, AZ, United States, 85016
United States, DC Washington DC, DC, United States, 20010
United States, GA Augusta, GA, United States, 30912
United States, MO St Louis, MO, United States, 63104
United States, NY Bronx, NY, United States, 10467
United States, NY New York, NY, United States, 10032
United States, OH Cincinatti, OH, United States, 45229